The evaluation of the changes in enzymatic antioxidant reserves and lipid peroxidation in chosen parts of the brain in an animal model of Parkinson disease

Ewa B. Romuk1, A–D, Wioletta Szczurek1, B–D, Michał Oleś2, B, C, Artur Gabrysiak3, B, C, Marta Skowron1, B, C, Przemysław Nowak2, A, E, F, Ewa Birkner1, E, F

1 Department of Biochemistry, Medical University of Silesia, School of Medicine with the Division of Dentistry, Zabrze, Poland
2 Department of Toxicology and Health Protection, Medical University of Silesia, School of Public Health, Katowice, Poland
3 FRYDA Medical Laboratory Ltd., Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of article


Abstract

**Background.** Parkinson’s disease is a progressive neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. The causes of Parkinson’s disease are not fully understood; however, increasing evidence implicates oxidative stress.

**Objectives.** The study was aimed at assessing the nature of the changes in the oxidation-antioxidant balance in the cerebral cortex, striatum, hippocampus, thalamus, and cerebellum in a rat model of Parkinson’s disease (PD).

**Material and methods.** Sixteen male Wistar rats were divided into 2 groups: I – control, II – Parkinson’s disease. The 8-weeks-old animals were decapitated, their brains removed and the following structures dissected and then frozen for further biochemical assays: cerebral cortex, striatum, hippocampus, thalamus and cerebellum. The activities of: the catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx), glutathione S-transferase (GST), superoxide dismutase (SOD) and the isoenzymes: Cu/ZnSOD and MnSOD; together with the malondialdehyde (MDA) and the total oxidative status (TOS) concentrations were measured in each structure.

**Results.** A significantly increased activities of SOD, Cu/ZnSOD, GST and reduced GR activity and an increase of MDA concentration were observed in the striatum of PD rats, comparing to the control group, combined with a significantly reduced activities of GR, SOD, Cu/ZnSOD and an increased GPX activity and MDA concentration in the hippocampus, a significantly lower GR, SOD, MnSOD, Cu/ZnSOD, and GST activities in the cerebral cortex. A significantly lower GR activity, higher CAT activity and MDA concentration in the thalamus and a significantly increased GR activity in the cerebellum were observed in PD rats compared to the corresponding control group.

**Conclusions.** Oxidative stress in PD involves many brain structures and various antioxidant enzymes and oxidative status parameters become dysfunctional, depending on the area of the brain, which might reflect the complexity of the clinical symptoms of PD.

**Key words:** oxidative stress, Parkinson disease, brain, antioxidant
Parkinson's disease (PD) is a progressive neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain, which results in a significant reduction in dopamine levels in the striatum. PD was the subject of many studies over the years; however, the factors causing selective neuronal cell death have not been clearly defined. Numerous studies suggest an increased exposure to free radicals, in combination with deficient antioxidant enzyme, might play an important role in neurodegeneration.\(^1,2\) PD is a multifactorial disease, and different mechanisms may be involved in the production of reactive oxygen species (ROS), and the interactions between them contribute to the severity of the degenerative processes of nerve cells.\(^3\) It is clear that the substantia nigra of the midbrain and the adjacent striatum are the most affected structures in the course of the analyzed disease. It should be noted, however, that the neurodegeneration in PD is not only limited to the dopaminergic pathways, but also include changes in other trails and structures of the brain, which can be damaged to varying degrees, reflecting the emergence of a variety of clinical symptoms.\(^1,4\)

6-hydroxydopamine (6-OHDA) used in the experiment is a neurotoxin, which, applied to the lateral ventricles of the brain, causes a persistent, lifelong destruction of the dopaminergic nigrostriatal pathway and profound deficits of dopamine in the striatum. The resulting damage is proposed as a near-ideal model of advanced stage Parkinson's disease, which mimics human PD.\(^5\)

The "free radical" hypothesis in PD has become the object of a number of experimental and clinical studies, but the role of oxidative stress and its devastating effects on different brain structures in PD have not been fully explained. Moreover, the results of studies on oxidative stress in PD are not homogeneous, and do not fully specify which antioxidant enzymes deplete and which indicators of oxidative stress are essential for the PD.\(^1,4\) In connection with data mentioned above, which is not fully precise in the available literature, this study was aimed to assess the role played by oxygen free radicals in the pathogenesis and course of PD, and to thoroughly evaluate the oxidation-antioxidant balance in the different structures of the brain (in the striatum, frontal cortex, hippocampus, thalamus, and cerebellum), in the experimental model of PD.

Material and methods

Animals

This experiment was performed on 16 male Wistar rats, weighing 180–200 g. The animals were housed under standard conditions of humidity (55–60%), temperature (21–22°C) and lighting (day-night: 12/12 h) throughout the experimental period, with unlimited access to food and filtered water. Experimental procedures with the use of animals were conducted in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The study protocol was approved by the Animal Experiments Local Ethics Committee of the Medical University of Silesia in Katowice (permit no. 33/2013). All efforts were made to minimize suffering.

Research project

Wistar newborns were divided into 2 groups and subjected to the following procedure:

- **Group I:** control rats: the 3-days-old neonatal rats were given desmethyldipramine in a dose of 20 mg/kg, intraperitoneally (IP) in a volume of 1.0 mL/kg and, after 60 min, 10 mL of 0.1% solution of ascorbic acid intraventriculally (ICV).
- **Group II:** rats with PD: the 3-days-old neonatal rats were given 20 mg/kg of desmethyldipramine IP in a volume of 1.0 mL/kg and, after 60 min, 6-hydroxydopamine in a dose of 15 mg/5 mL in 0.1% ascorbic acid solution into the right and left lateral ventricle of the brain.

The newborns were housed with their mothers until the age of 4 weeks, separated by gender and placed in separate cages for breeding thereon. After reaching the 8-week, the rats were decapitated. Then, after the opening the skull, brains were removed and the following structures of the brain were dissected: frontal cortex, striatum, hippocampus, thalamus, and cerebellum. The tissues were weighed and frozen on solidified CO\(_2\) (so-called “dry ice”) and stored for further biochemical assays at -80°C.

Tissues preparation

Tissues were homogenized on ice, an UP50H ultrasonic processor (Hielscher) was used. The homogenates were centrifuged at 3000 rpm for 10 min, and supernatant was used for assay of the oxidant-antioxidant parameters.

Biochemical analysis

Glutathione reductase (GR) activity was measured by the modified method by Richterich.\(^6\) This method is based on a determination of changes in the concentration of reduced NADPH, which reacts with oxidized glutathione. The activity of GR was expressed as μmol of NADPH per minute per gram of protein (IU/g protein). The method is absolutely specific for glutathione reductase. Glutathione peroxidase (GPx) activity was measured by the kinetic method of Paglia and Valentine.\(^7\) In this method, GPx catalyzes the reaction between reduced glutathione (GSH) and t-butyl hydroperoxide. The resulting oxidized glutathione (GSSG) is then converted back to the reduced form (GSH) by a NADPH-dependent glutathione reduc-
tase (GR). The activity of GPx was expressed as micro-
moles of NADPH oxidized per minute normalized to
gram of protein (IU/g Hb). Glutathione transferase (GST)
activity was determined by kinetic method according to
Habig. GST activity was expressed as μmol of thio-
exane formed within 1 min per gram of protein (IU/g Hb).
The method of Oyanagui was used to measure the ac-
tivity of superoxide dismutase (SOD) and its izoenzymes:
the cytoplasmatic Cu/Zn-superoxide dismutase (Cu/Zn-
SOD) and the mitochondrial Mn-superoxide dismutase
(MnSOD) in brain’s homogenates. In this method, xan-
thine oxidase produces superoxide anions which react
with hydroxylamine forming nitric ions. These ions react
with naphthalene diamine and sulfanilic acid generating
a colored product. The concentration of this product is
proportional to the amount of produced superoxide an-
ions and negatively proportional to the activity of SOD.
The enzymatic activity of SOD was expressed in nitric
units. The activity of catalase was expressed as units per mil-
gram of protein (IU/mg protein). The malondialdehyde
(MDA) level was determined by the Ohkawa method us-
ing a Perkin Elmer LS45 spectrofluorometer. The concen-
tration of MDA was expressed as mol/g of protein.

### Statistical analysis

All statistical analyses were based on STATISTICA v. 10
program (StatSoft, Polska). The normality of the results
distribution was verified using the Kolmogorov-Smirnov
test, whereas Levene’s test was used to verify homogeneity
of variances. The data was analyzed using non-parametric
Mann-Whitney U test and they were presented as median
with the first and fourth quartiles. Value of p < 0.05 was
considered to be statistically significant.

### Results

In the cortex of the studied rats we have observed sta-
tistically significant decrease in GR (29%), SOD (29%),
MnSOD (25%) and CuZnSOD (31%) activities in the
6-OHDA group compared to that of the control rats
(Table 1).

Results observed in the striatum showed us statistically
significant increase in GST (25%), SOD (25%), CuZnSOD
(15%) activities and increase in MDA concentration (18%)
activity in the 6-OHDA group compared to that of the
control rats. GR activity decreased in the 6-OHDA group
(11%) compared to that of the control rats (Table 2).

<table>
<thead>
<tr>
<th>Cortex</th>
<th>Control</th>
<th>6–OHDA</th>
<th>p–value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD [IU/g protein]</td>
<td>4.31 [4.21–4.78]</td>
<td>3.22 [3.12–4.01]</td>
<td>0.001</td>
</tr>
<tr>
<td>CAT [kIU/g protein]</td>
<td>29.59 [28.30–34.00]</td>
<td>25.63 [22.43–35.60]</td>
<td>ns</td>
</tr>
<tr>
<td>MDA [µmol/g protein]</td>
<td>1.22 [1.13–1.23]</td>
<td>1.06 [0.93–1.34]</td>
<td>ns</td>
</tr>
</tbody>
</table>

### Table 2. Antioxidant enzymes activity and malondialdehyde concentration in striatum of studied groups of rats
(U Mann–Whitney test)

<table>
<thead>
<tr>
<th>Striatum</th>
<th>Control</th>
<th>6–OHDA</th>
<th>p–value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GR [IU/g protein]</td>
<td>12.46 [10.94–12.99]</td>
<td>10.89 [10.54–11.59]</td>
<td>0.03</td>
</tr>
<tr>
<td>MnSOD [IU/g protein]</td>
<td>16.90 [15.96–18.33]</td>
<td>20.77 [18.63–23.40]</td>
<td>0.009</td>
</tr>
<tr>
<td>MDA [µmol/g protein]</td>
<td>0.83 [0.8–0.87]</td>
<td>0.96 [0.88–1.09]</td>
<td>0.03</td>
</tr>
</tbody>
</table>

In the hippocampus we have observed increase in GPX
activity (15%) and MDA concentration (10%) and de-
crease in GR (18%), SOD (14%), CuZnSOD (16%) activity
in the 6-OHDA group compared to that of the control
rats (Table 3).

Results observed in the thalamus showed us statisti-
cally significant decrease in the GR activity (16%) and
increase in CAT activity (30%) and MDA concentration
(14%) in the 6-OHDA group compared to that of the con-
tral rats (Table 4).

In the cerebellum we have observed statistically signifi-
cant increase in GR activity (26%) in the 6-OHDA group
compared to that of the control rats (Table 5).
Table 3. Antioxidant enzymes activity and malondialdehyde concentration in hippocampus of studied groups of rats (U Mann-Whitney test)

<table>
<thead>
<tr>
<th>Hipocampus</th>
<th>Control</th>
<th>6–OHDA</th>
<th>p–value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPX [IU/g protein]</td>
<td>8.47 [8.02–9.06]</td>
<td>9.86 [9.18–10.83]</td>
<td>0.02</td>
</tr>
<tr>
<td>CAT [kIU/g protein]</td>
<td>42.36 [39.86–43.14]</td>
<td>41.73 [40.10–43.70]</td>
<td></td>
</tr>
<tr>
<td>SOD [NU/mg protein]</td>
<td>18.57 [17.56–18.86]</td>
<td>17.77 [16.51–18.50]</td>
<td>0.05</td>
</tr>
<tr>
<td>MDA [umol/g protein]</td>
<td>1.02 [0.96–1.05]</td>
<td>1.07 [0.90–1.20]</td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Antioxidant enzymes activity and malondialdehyde concentration in thalamus of studied groups of rats (U Mann-Whitney test)

<table>
<thead>
<tr>
<th>Thalamus</th>
<th>Control</th>
<th>6–OHDA</th>
<th>p–value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GR [IU/g protein]</td>
<td>7.43 [6.79–8.04]</td>
<td>6.58 [6.03–6.60]</td>
<td>0.03</td>
</tr>
<tr>
<td>CAT [kIU/g protein]</td>
<td>25.22 [22.96–35.01]</td>
<td>36.09 [30.60–41.10]</td>
<td>0.04</td>
</tr>
<tr>
<td>MnSOD [NU/mg protein]</td>
<td>5.95 [5.24–6.68]</td>
<td>5.90 [5.20–6.50]</td>
<td></td>
</tr>
<tr>
<td>MDA [umol/g protein]</td>
<td>0.57 [0.51–0.67]</td>
<td>0.59 [0.54–0.68]</td>
<td></td>
</tr>
</tbody>
</table>

Table 5. Antioxidant enzymes activity and malondialdehyde concentration in thalamus of studied groups of rats (U Mann-Whitney test)

<table>
<thead>
<tr>
<th>Cerebellum</th>
<th>Control</th>
<th>6–OHDA</th>
<th>p–value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GR [IU/g protein]</td>
<td>7.74 [6.86–8.24]</td>
<td>10.23 [8.03–11.65]</td>
<td>0.03</td>
</tr>
<tr>
<td>GST [IU/g protein]</td>
<td>2.22 [2.13–2.35]</td>
<td>2.09 [1.59–2.36]</td>
<td></td>
</tr>
<tr>
<td>CAT [kIU/g protein]</td>
<td>51.33 [48.65–61.50]</td>
<td>50.48 [47.81–65.45]</td>
<td>0.04</td>
</tr>
<tr>
<td>MnSOD [NU/mg protein]</td>
<td>5.51 [5.17–6.56]</td>
<td>6.04 [4.52–6.98]</td>
<td></td>
</tr>
<tr>
<td>MDA [umol/g protein]</td>
<td>0.75 [0.69–0.86]</td>
<td>0.61 [0.46–0.76]</td>
<td></td>
</tr>
</tbody>
</table>

Discussion

The balance of the oxidation-antioxidant system in neurodegenerative diseases has been the subject of intense experimental and clinical studies over the past few years. Plentiful evidence suggests that the cell aging processes and progressive neurodegeneration are closely associated with oxidative stress. Although the definitive cause of nigral dopamine neuron loss remains unknown, oxidative stress is the greatest risk factor for PD. Oxidative stress has been defined as a state of impaired oxidation-antioxidant balance, in the direction of oxidation, which is caused by excessive production of ROS and antioxidant mechanisms inability to detoxify them. Even though there are numerous defense mechanisms against free radicals in the body, it appears that the brain is exposed to an increasingly damaging effects of ROS compared to peripheral organs. Although the adult human brain represents only 2% of the total body weight, it consumes almost 20% of the total amount of oxygen absorbed by the body. Such excessive oxidative metabolism favors the generation of oxygen free radicals. Excessive ROS generation is harmful to the cell membrane and may damage the nerve cells. Additionally, the high levels of polyunsaturated fatty acids in cell membranes of neurons and relatively low levels of antioxidants in brain tissues, as compared to other organs, make them more susceptible to the damage caused by ROS.

Nerve cells are protected from the damaging effect of ROS under physiological conditions, but in the course of PD the depletion of the reserves of the antioxidant mechanisms is observed. Our results show that in the striatum of the rats with PD, the severity of oxidative stress is observed, as evidenced by the significantly higher level of MDA compared to healthy individuals. MDA is a marker of lipid peroxidation, which is significantly accumulated in striatum of the subjects with PD, as compared to the other areas of the brain and comparing to the control group. In addition, we observed a significant increase in the activity of SOD, Cu/ZnSOD, GST, and a serious reduction in the activity of the GR in the striatum of the subjects with PD, compared to the control group. On the other hand, another study has shown that the antioxidant activity is reduced in the striatum of the rats with PD and it appears to be a key determinant of the susceptibility to damage of the dopaminergic neurons. These differences between the results can be explained on the basis of the duration of the test, because the longer the observation...
time, the greater is the extent of the marked symptoms of the increased oxidative stress. Our results indicate a stimulation of the antioxidant system in response to the increased lipid peroxidation and an increase in the free radicals levels, which is aimed to protect the nerve cells from oxidative damage. It is believed that this increase may be temporary. The defense mechanisms are depleted as a result of continuously sustained oxidative stress, which is observed in PD.

An important role for the protection of neurons against oxidative stress is played by SOD and its 2 fractions: Cu/ZnSOD, and MnSOD. Those enzymes catalyze the removal of the toxic superoxide radical by converting it into hydrogen peroxide and molecular oxygen. Research indicates that overexpression of SOD and its isoenzymes may protect efficiently against neuronal loss. The authors of the research indicate that GSH might indicate clinical susceptibility to the development of PD. The study by Zhou et al. also showed GSH depletion in the substantia nigra of midbrain of patients with PD. The depletion of GSH indicates that overexpression of SOD and its isoenzymes may be temporary. The defense mechanisms are depleted as a result of continuously sustained oxidative stress, which is observed in PD.

In turn, glutathione reductase catalyzes the reduction of the oxidized form of glutathione (GSSG) in the presence of NADPH, the donor of electron necessary to restore the reduced form of glutathione (GSH). GSH depletion rate correlates positively with the severity of the disease and the ratio of GSH/GSSG is an important indicator of the loss of dopaminergic neurons. The GSH deficiency causes an increase of the H_{2}O_{2} concentration, which is continuously produced by the mitochondria in the brain, and its detoxification in the brain is carried out by GSH-dependent mechanisms; therefore, GR activity impairment causes GSH deficiency, and this contributes to the inability of H_{2}O_{2} neutralization by GPx, which requires the presence of GSH. A previous study by Pearce et al. also showed GSH depletion in the substantia nigra of midbrain of patients with PD. The depletion of GSH might indicate clinical susceptibility to the development of PD. The authors of the research indicate that GSH can be used as a biomarker for the diagnosis of these neurodegenerative diseases. Therefore, the activity of GSH-dependent enzymes may indirectly indicate the progression of the disease. The study by Zhou et al. suggests a possible correlation between severe dopamine oxidation and reduced protective potential of GSH. Additionally, the reduced GSH level significantly impairs the protective capacity of the brain from the toxic impacts of the oxidized dopamine molecules and ROS. The other enzyme along with the increased activity, which has been observed in the striatal of the subjects with PD, also plays an important role in protecting the tissues from free radicals. GST catalyzes the conjugation of glutathione with nucleophiles and electrophiles, resulting in the formation of glutathione conjugates.

In addition to the degeneration of dopaminergic neurons in the striatum, extensive neurodegeneration and atrophy is observed in other types of nerve cells in the brain, including areas such as hippocampus, thalamus, cortex and cerebellum. This damage may cause the appearance of symptoms other than characteristic motor symptoms, which include, inter alia, cognitive impairments, affective changes, depression, psychosis, memory deficits and other non-motor symptoms. The chronic exposure to ROS can cause atrophy and abnormal functioning in many key areas of the brain structures, including the hippocampus and frontal cortex. It has been proved that atrophy of the hippocampus may be a biomarker of the early stages of cognitive disorders and memory disorders in patients with PD. Furthermore, cell damage in various regions of the brain reduces cognitive ability, causes deterioration of memory function, an increase of anxiety and depression levels in older rats with reduced dopamine and serotonin levels, in comparison with the group of young subjects. It seems that ROS may be involved in the processes damaging the hippocampus and cerebral cortex, because their long-lasting high levels lead to the failure of antioxidant systems. Our studies also confirm this theory. They have also shown a significant reduction in the activity of GR, SOD, Cu/ZnSOD and higher GPx activity and an increase of MDA production in the hippocampus of rats with PD, compared to the control group, and a significantly lower activity of GR, SOD, MnSOD, CuSOD, and GST in the cerebral cortex of rats with PD group, as compared to healthy rats. A study conducted by Che et al. has shown that chronic stress resulting in ROS overproduction might damage the cerebral cortex and the hippocampus, which manifests in the reduced activity of antioxidant enzymes in the brains of rats exposed to chronic stress compared to the control group. Moreover, this study showed that reducing the antioxidant ability and induction of the lipid peroxidation in the cerebral cortex and hippocampus correlates positively with the severity of memory impairment, a decrease in learning abilities and the severity of depression. Looking at this study, it appears likely that the overproduction of free radicals and the progressive nature of PD supports the possibly negative impact of ROS in many areas of the brain, which reflects the appearance of clinical symptoms independent from the deficiency of dopamine and dopaminergic neurons. It is suggested that the overproduction of ROS is associated with a decrease in the antioxidant defense system during aging or as a result of an ongoing disease, which leads to the failure of cell homeostasis. Reduced expression or antioxidant deficiency may lead to excessive ROS production, and there is no possibility of removing them. Thalamus plays an important role in the proper communication between each brain structure. It is also responsible for the initial evaluation of sensory stimuli and then communicating this information from the first-order kernel to the cortex, while the higher-order kernel transmits the information from one area of the cortex to another. Thalamus plays a key role in the integration of sensory and motor information and attention processes, using cortico-thalamic loops.
has connections to the hypothalamus and hippocampus. The cerebellum receives information from multiple brain systems; it is also responsible for maintaining balance of the body, coordination and dexterity and maintaining proper muscle tone, among other things. Our study shows that a significantly lower activity of GR, higher CAT activity and an increase in the concentration of MDA is observed in the thalamus of rats with PD, and a significantly higher activity of GR is detected in the cerebellum of rats with PD, compared to the corresponding control group. Our study indicates that in the case of a reduction in GR activity in the striatum, the brain is compensated for the activity of other antioxidant enzymes. The presence of antioxidants in the brain structures including the striatum, hippocampus, thalamus, and cerebellum is devoted to protecting brain cells from damage caused by ROS.

Our research shows that oxidative stress in PD involves many brain structures and various antioxidant enzymes and oxidative status parameters. Depending on the area of the brain, the differences in the scope of changes in the antioxidant enzymes activity are apparent. The mechanisms of oxidative damage are regional and specific. It seems that every cell or tissue has its own ROS defense system and in various areas under oxidative stress, different antioxidant enzymes are present. Specificity of the area may be related to the damage of various structures of the brain reflects the complex nature of the clinical symptoms of PD. Thus, the study on PD should not be limited to the analysis of changes in the substantia nigra and the striatum, but should also consider other brain structures, the failure of which manifests itself in the form of clinical symptoms other than those of locomotor disorders. Future clinical and experimental studies should be directed to investigate molecular mechanisms of the neuronal damage by ROS. Understanding them may help in developing new approaches to neuroprotection. Further research aimed at extending the knowledge about the specific mechanisms responsible for the modulation of ROS production in specific areas of the brain, is also required. In the available literature, only a few studies focus on the role of oxidative stress in damaging the brain structures other than the striatum in PD; therefore, there is a need for further studies, which will aim at expanding the concept presented by us.

References

28. van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA. Depressive symptoms in Parkinson’s disease are related...
